ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has received a consensus recommendation of "Buy" from the nine research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $80.13.
A number of brokerages have recently issued reports on ANIP. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. StockNews.com lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. Finally, Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st.
Read Our Latest Research Report on ANIP
ANI Pharmaceuticals Stock Performance
Shares of ANIP stock traded up $2.26 during mid-day trading on Thursday, reaching $72.95. 322,989 shares of the company's stock traded hands, compared to its average volume of 282,027. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a 50 day moving average price of $65.61 and a two-hundred day moving average price of $60.32. The firm has a market capitalization of $1.59 billion, a PE ratio of -132.64 and a beta of 0.49. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $73.16.
Insider Transactions at ANI Pharmaceuticals
In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,200 shares of company stock worth $197,792. 11.10% of the stock is currently owned by corporate insiders.
Institutional Trading of ANI Pharmaceuticals
Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock worth $854,000 after acquiring an additional 1,972 shares in the last quarter. Franklin Resources Inc. grew its position in shares of ANI Pharmaceuticals by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after purchasing an additional 691 shares during the period. Barclays PLC raised its holdings in shares of ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after acquiring an additional 135,003 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of ANI Pharmaceuticals by 6.6% in the 4th quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company's stock valued at $762,000 after purchasing an additional 858 shares during the period. 76.05% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
(
Get Free ReportANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Stories
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
